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Introduction 
            The decision to initiate pharmacological intervention in case of fetal tachycardia depends
on several factors and must be weighed against possible maternal and/or fetal adverse effects
inherent to the use of antiarrhythmics. 
            First, the seriousness of the fetal condition must be recognized. Many studies have shown
that in case of fetal tachycardia, there is a significant predisposition to congestive heart failure
and subsequent development of fetal hydrops and even sudden cardiac death1,2,3
            Secondly, predictors of congestive heart failure have been suggested in several studies,
such as the percentage of time that the tachycardia is present, the gestational age at which the
tachycardia occurs4, the ventricular rate5 and the site of origin of the tachycardia6. However, the
sensitivity of these predictors is low and they are therefore clinically not very useful. In addition,
hemodynamic compromise may occur in less than 24 - 48 hours as has been shown in the fetal
lamb7  and in tachycardic fetuses8,9. On the other hand, spontaneous resolution of the tachycardia
has also been described10. 
            Thirdly, transplacental management of fetuses with tricuspid regurgitation11, congestive
heart failure or fetal hydrops is difficult12,13, probably as a result of limited transplacental transfer
of the antiarrhythmic drug14,15. In case of fetal hydrops, conversion rates are decreased and time
to conversion is increased13. 
            Treatment of sustained fetal tachycardia is therefore to be preferred above expectant
management, although some centers oppose this regimen and suggest that in cases with
(intermittent)   fetal   SVT   not   complicated   by   congestive   heart   failure   or   fetal   hydrops,
conservative management and close surveillance might be a reasonable alternative16,17,18.  
            The most important goal of initiation of treatment is the prevention or resolution of
hemodynamic compromise and therefore the prevention of fetal hydrops. In case of treatment the
question remains whether to treat prenatally or postnatally, in the latter case after artificial
preterm delivery. Several factors play a role in this decision. In case of transplacental treatment,
the fetus will be able to thrive in its natural environment and the problems encountered with a
preterm delivery will be avoided. One may oppose however, that, with elective preterm delivery
and postnatal treatment, monitoring of the infant might be easier. In case of an emergency
situation, for instance ventricle fibrillation, physicians may be able to react instantly. But, there is
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no guarantee of a favourable outcome of this situation in the postnatal setting. This view seems
to result in a redirection of the problem in responsibility between different specialties and
predisposes the neonate to additional complications of prematurity19,20. In addition, an induced
preterm delivery, is likely to result in a caesarean section with increased maternal risks and
possible effects on subsequent pregnancies21,22,23. The decision as to prenatal or postnatal
initiation of treatment mainly depends on gestational age and it is obvious that at an early
gestation prenatal treatment is the only reasonable alternative. At term, physicians may differ in
opinion whether to treat pre- or postnatally. However, transplacental treatment has proven to be
both safe and effective, and serious maternal adverse effects, although theoretically possible,
have not been described in literature. It seems therefore logical to treat the fetus in its natural
environment through transplacental treatment. 
Direct fetal treatment
            Transplacental therapy should be the mode of therapy in nonhydropic fetuses and first
choice in hydropic fetuses. However, when conversion to sinus rhythm is not achieved with
several maternally administered antiarrhythmic drugs, one may opt for direct fetal therapy.
            In the international literature, several modes of administration, intra-umbilical, intra-
amniotic, intra-peritoneal, intra-muscular and intra-cardiac, have been described  12,13,24. The
routes of administration all have their specific characteristics. An intra-umbilical injection allows
direct access to the fetal circulation and thereby the potential for a quick response to therapy, a
characteristic also observed with intra-cardiac injections. However, both of these invasive
measures pose a significant risk to the fetus. Intra-peritoneal, intra-amniotic and intra-muscular
injections (preferably in the buttock of the fetus), pose less risk to the fetus and provide a more
sustained release of the medication. 
               If one chooses to opt for direct fetal therapy, one must bear in mind that the
antiarrhythmic   drug   will   probably   distribute   to   the   maternal   compartment,   unless   this
compartment is primed with the drug. Therefore, direct fetal therapy should always be
administered as an adjunct to maternal administration. In addition, intra-muscular or intra-
peritoneal injections that provide a more sustained release into the fetal circulation, as well as an
antiarrhythmic drug with a long half-life are to be preferred as this will minimize the number of
invasive procedures required.
            These ways of administration show a significant mortality, but it is unclear if these deaths
are attributable to the invasive nature of the treatment or to the severity of the underlying
condition12,25. The direct fetal treatment approach should only be used in cases of fetal
tachycardia complicated by hydrops with resistance to transplacental multidrug therapy.
Transplacental treatment
            Numerous drugs have been proposed in the international literature for the treatment of
fetal tachycardia. The most used and successful drugs are digoxin, sotalol, flecainide and
amiodarone. This review article will focus on these drugs.
Digoxin
               Digoxin, a digitalis glycoside, has positive inotropic and negative chronotropic
properties, resulting in an increase in cardiac output and a decrease in heart rate. In addition, it
prolongs the refractoriness of the AV node. Digoxin has been the drug of first choice in many
centers, and is probably the most used drug in the treatment of fetal tachycardia. Reported
fetal:maternal(F:M) plasma concentration ratios vary between 0.4 and 0.926,27,28. However, in
case of fetal hydrops, this ratio is reduced, which may result in failure of treatment. Conversion
to sinus rhythm is achieved in approximately 50 % in nonhydropic SVT and of 45% in
AF29,30,31,32. In tachycardia complicated by hydrops, disappointing conversion rates of 15-25 %
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have been reported33,34. It has few adverse effects, and is relatively safe to use. Maternal adverse
effects are confined to nausea, vomiting and headache, mostly related to overdosing. Cardiac
adverse effects are ventricular extrasystoles and heart block. Digoxin seems to have a relatively
low fetal mortality rate. 
            In conclusion, digoxin is a safe drug in the treatment of fetal tachycardia, however, its use
results in relatively low conversion rates, and frequently second line drugs are required to
achieve sinus rhythm. Some reports have suggested intravenous administration of digoxin, which
may be a more effective approach35 .
 
Flecainide
               Flecainide, a class IC antiarrhythmic agent, depresses conduction throughout the
myocardium and prolongs the refractory period. It has been proposed as an effective drug in the
treatment of SVT, especially SVT associated with hydrops, either as drug of first choice or in
combination with digoxin. The transplacental transfer is good, with F:M ratios ranging from 0.5
to   0.9736,37,38.   Several   studies   have   provided   us   with  valuable   data,   reporting  excellent
conversion rates. It has been used as drug of second choice in nonhydropic SVT, and drug of
first choice in hydropic SVT resulting in conversion rates ranging from 75 – 92 %39,40,41. 
               The   adverse   effects   of  flecainide  are  dizziness,   headache,   visual  disturbances,
paresthesia, tremors, flushing, nausea and vomiting. The main concern with the use of flecainide
is that in the Cardiac Arrhythmia Suppressoin Trial (CAST), a placebo controlled trial in patients
with premature beats after myocardial infarction, there was an increased mortality rate in the
flecainide group42. Therefore it is suggested that its use should be restricted to life-threatening
arrhythmias. Its use in fetal tachycardia therefore is mainly concentrated on SVT complicated by
hydrops. It has been associated with intra-uterine deaths, however, the occurrence of an intra-
uterine death is a well known complication in fetal hydrops, and we can only speculate on the
exact relationship with flecainide.
            In conclusion, flecainide is a very potent drug in the treatment of SVT, with or without
hydrops. Caution is however, required. It should not be used in fetal AF as it may increase the
ventricular response.
Amiodarone
               Amiodarone, a class III antiarrhythmic agent, prolongs the repolarization of the
myocardium. The drug has received some attention in the past43,44,45, but has gained much
popularity lately. The transplacental transfer is relatively low, F:M ratio of 0.2 – 0.446. Data on
the use of amiodarone was until recently confined to case reports and some small studies, with
success rates of approximately 50 %, bearing in mind that it mostly concerned cases in which
other treatment options had failed. Recently, a large study by Strasburger et al. was published in
which amiodarone was initiated in drug-refractory fetal tachycardia complicated by hydrops. A
high success rate of 93 % in SVT was accomplished, and a lower conversion rate of 33 % in
AF47.    
            The adverse effects of amiodarone are of possible concern: in some neonates a mild
transient biochemical hypothyroidism was detected, which required treatment in only 1 neonate
who received amiodarone for a prolonged period after birth. In one mother, treatment had to be
stopped because of the development of a photosensitive skin rash and thrombocytopenia. No
intra-uterine deaths occurred in this study.
               In conclusion, amiodarone is a very successful drug, and suitable as second line
treatment, especially in hydropic SVT. 
Sotalol
            Sotalol is a β blocking agent with additional class III antiarrhythmic properties. Several
studies in the past years have shown its efficacy, and it has been encorporated in many treatment
protocols.
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            The transplacental transfer is excellent with a F:M ratio of 1:148. The success rate of
sotalol as a single therapy in the treatment of atrial flutter in the reported studies was
approximately 65 %, and reached 80 % after the addition of digoxin49. This compares favorably
with other reports32  and it is concluded that sotalol is a superior drug in the treatment of AF,
both nonhydropic as hydropic. The success rate in fetal SVT was approximately 55 % with
sotalol as a single drug and reached 75 % after the addition of digoxin. These results are
comparable with other proposed treatment protocols. Maternal adverse effects are not frequent,
and mostly related to its β blocking properties. However, sotalol has been associated with intra-
uterine deaths, mainly in hydropic cases with SVT50. Ventricle fibrillation might have been the
cause of death and therefore, proarrhythmic effects of sotalol are of concern.
            In conclusion, sotalol is a very potent drug in the treatment of fetal AF, with or without
hydrops, and is recommended as drug of first choice. In SVT, caution is required and the risk of
proarrhythmia should be minimized, low initiation dosages and stepwise dosage increases are
recommended.   In   addition,   close   monitoring,   especially   during   the   initiation   phase   is
recommended. Sotalol seems contraindicated in SVT complicated by hydrops.
Conclusions
            Fetal tachycardia is a serious condition in which the fetus is at significant risk for fetal
hydrops, neurological damage and intra uterine death. In cases with intermittent tachycardia and
no signs of hemodynamical compromise, one may opt for expectant management (close
monitoring is mandatory), however, in case of sustained tachycardia we strongly recommend to
initiate   transplacental   treatment.   Treatment   of   fetal   tachycardia   should   be   executed   in
experienced maternal-fetal medicine centers and close monitoring of fetal well-being by
ultrasound, especially in the initiation phase, is recommended. Before initiation of therapy, pre-
existing maternal arrhythmias and/or a prolonged QT segment should be excluded by a thorough
examination of medical history and a maternal ECG. It is wise to have the maternal ECG
repeated during treatment, especially in case of dosage increase, or the addition of second-line
treatment.
            On the basis of the international literature and personal experience we have developed
several treatment protocols. In case of fetal AF, either hydropic or nonhydropic, we advocate
sotalol as drug of first choice, and digoxin as drug of second-choice (Utrecht protocol 1). In
case of fetal SVT without hydrops, we recommend digoxin as drug of first choice and sotalol as
drug of second choice (Utrecht protocol 2). In case of fetal SVT complicated by hydrops two
options are available, either flecainide as drug of first choice and digoxin as second choice, or
digoxin intravenous (maternal), followed by amiodarone as drug of second choice (Protocol 3).
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Utrecht Protocol 1: Fetal Atrial Flutter
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Utrecht Protocol 2: Fetal Nonhydropic SVT
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Protocol 3: Fetal Hydropic SVT
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